SHANGHAI KAIBAO's wholly-owned subsidiary has obtained a drug registration certificate
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, SHANGHAI KAIBAO announced that its wholly-owned subsidiary Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd. (referred to as "subsidiary") recently received the Drug Registration Certificate for Doxofylline Tablets issued by the National Medical Products Administration. Doxofylline Tablets are suitable for bronchial asthma, asthmatic chronic bronchitis, and other respiratory difficulties caused by bronchospasm
According to the Zhitong Finance APP, Shanghai Kaibao (300039.SZ) announced that its wholly-owned subsidiary Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd. (referred to as "subsidiary") recently received the Drug Registration Certificate for Doxofylline Tablets issued by the National Medical Products Administration. Doxofylline Tablets are suitable for bronchial asthma, wheezing chronic bronchitis, and other bronchospasm-induced respiratory difficulties